Aerie Pharmaceuticals

Aerie Pharmaceuticals is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.

Can Aerie Pharmaceuticals Go From 1.5% of the Glaucoma Market to 40%?

Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.

Why Aerie Pharmaceuticals Crashed 22.4% Today

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q3 2019 Results - Earnings Call Transcript

The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.

Is Aerie Pharmaceuticals a Buy ?

A new slide deck shows reasons for optimism.

Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today

Amazon

Salesforce

Concho Resources

Dropbox

Diamondback Energy

Nutanix

Revance Therapeutics

Boingo Wireless

Yext

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

10 Monster Growth Stocks to Buy for 2019 and Beyond

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound?

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2019 Results - Earnings Call Transcript

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know

Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

Aerie Completes Enrollment Under Rhopressa Study in Japan

Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?

Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

Aerie Pharmaceuticals Inc. (AERI) CEO Vicente Anido on Q1 2019 Results - Earnings Call Transcript

Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound?

Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

News for Aerie Pharmaceuticals Stock (AERI)